Search Results - "Kerbel, Robert S."

Tumor Angiogenesis by Kerbel, Robert S

“…The dependency of the growth of tumors on blood vessels, once considered a doubtful proposition, has become a major avenue of research and drug development…”
Get full text

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect by Bocci, Guido, Kerbel, Robert S.

“…Key Points Metronomic chemotherapy is the frequent, regular administration of drug doses designed to maintain low, but active, concentrations of…”
Get full text

Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? by Kerbel, Robert S

“…For more than 50 years, a major goal of research in cancer therapeutics has been to develop universally effective agents that render cancer cells more…”
Get full text

Mouse models of advanced spontaneous metastasis for experimental therapeutics by Francia, Giulio, Kerbel, Robert S, Cruz-Munoz, William, Man, Shan, Xu, Ping

“…The successful systemic therapy of advanced visceral metastatic disease remains a daunting challenge, but this therapeutic circumstance has rarely been…”
Get full text

A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment by Kerbel, Robert S

“…The clinical circumstance of treating spontaneous metastatic disease, after resection of primary tumors, whether advanced/overt or microscopic in nature, is…”
Get full text

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis by Ebos, John M. L, Kerbel, Robert S

“…The progression-free survival benefits from approved antiangiogenic drugs are modest and are frequently not accompanied by overall survival improvements…”
Get full text

Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR by Al-Nedawi, Khalid, Meehan, Brian, Kerbel, Robert S, Allison, Anthony C, Rak, Janusz

“…Activated EGF receptor (EGFR) plays an oncogenic role in several human malignancies. Although the intracellular effects of EGFR are well studied, its ability…”
Get full text

The multifaceted circulating endothelial cell in cancer: towards marker and target identification by Bertolini, Francesco, Shaked, Yuval, Mancuso, Patrizia, Kerbel, Robert S

“…Increases in the number of circulating endothelial cells (CECs) and progenitors (CEPs) have been reported in various pathological conditions including cancer…”
Get full text

miR-30b/30d Regulation of GalNAc Transferases Enhances Invasion and Immunosuppression during Metastasis by Gaziel-Sovran, Avital, Segura, Miguel F., Di Micco, Raffaella, Collins, Mary K., Hanniford, Douglas, Vega-Saenz de Miera, Eleazar, Rakus, John F., Dankert, John F., Shang, Shulian, Kerbel, Robert S., Bhardwaj, Nina, Shao, Yongzhao, Darvishian, Farbod, Zavadil, Jiri, Erlebacher, Adrian, Mahal, Lara K., Osman, Iman, Hernando, Eva

“…To metastasize, a tumor cell must acquire abilities such as the capacity to colonize new tissue and evade immune surveillance. Recent evidence suggests that…”
Get full text

The anti-angiogenic basis of metronomic chemotherapy by Kerbel, Robert S, Kamen, Barton A

“…In addition to proliferating cancer cells and various types of normal cells, such as those of the bone marrow, conventional cytotoxic chemotherapeutics affect…”
Get full text

Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models by Bridgeman, Victoria L, Vermeulen, Peter B, Foo, Shane, Bilecz, Agnes, Daley, Frances, Kostaras, Eleftherios, Nathan, Mark R, Wan, Elaine, Frentzas, Sophia, Schweiger, Thomas, Hegedus, Balazs, Hoetzenecker, Konrad, Renyi‐Vamos, Ferenc, Kuczynski, Elizabeth A, Vasudev, Naveen S, Larkin, James, Gore, Martin, Dvorak, Harold F, Paku, Sandor, Kerbel, Robert S, Dome, Balazs, Reynolds, Andrew R

“…Anti‐angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via…”
Get full text

Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy by EBOS, John M. L, LEE, Christina R, KERBEL, Robert S

“…Despite early benefits seen in cancer patients treated with antivascular endothelial growth factor (VEGF) pathway-targeted drugs, the clinical benefits…”
Get full text

Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma by Kuczynski, Elizabeth A, Lee, Christina R, Man, Shan, Chen, Eric, Kerbel, Robert S

“…Acquired evasive resistance is a major limitation of hepatocellular carcinoma (HCC) treatment with the tyrosine kinase inhibitor (TKI) sorafenib. Recent…”
Get full text

Glioma Tumor Stem-Like Cells Promote Tumor Angiogenesis and Vasculogenesis via Vascular Endothelial Growth Factor and Stromal-Derived Factor 1 by FOLKINS, Chris, SHAKED, Yuval, SHAN MAN, TANG, Terence, LEE, Christina R, ZHENPING ZHU, HOFFMAN, Robert M, KERBEL, Robert S

“…Cancer stem cells (CSC) are predicted to be critical drivers of tumor progression due to their self-renewal capacity and limitless proliferative potential. An…”
Get full text

Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors by FOLKINS, Chris, SHAN MAN, PING XU, SHAKED, Yuval, HICKLIN, Daniel J, KERBEL, Robert S

“…Vascular endothelial cells have been identified as a critical component of the neural stem cell niche, raising the possibility that brain tumor stem-like cells…”
Get full text

Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease by Wu, Florence T. H., Xu, Ping, Chow, Annabelle, Man, Shan, Krüger, Janna, Khan, Kabir A., Paez-Ribes, Marta, Pham, Elizabeth, Kerbel, Robert S.

“…Background There are phase 3 clinical trials underway evaluating anti-PD-L1 antibodies as adjuvant (postoperative) monotherapies for resectable renal cell…”
Get full text

A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis by Khan, Kabir A, Kerbel, Robert S

“…Targeting the metastatic process is a critical pursuit in the treatment of malignant disease. There are currently no specific anti‐metastatic drugs approved…”
Get full text

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models by Hackl, Christina, Man, Shan, Francia, Giulio, Milsom, Chloe, Xu, Ping, Kerbel, Robert S

“…Advanced and recurrent diseases are the major causes of death in colon cancer. No standard preclinical model addresses advanced disease and spontaneous…”
Get more information

Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers by Schito, Luana, Rey, Sergio, Xu, Ping, Man, Shan, Cruz‐Muñoz, William, Kerbel, Robert S

“…Conventional maximum‐tolerated dose (MTD) chemotherapy relies on periodic, massive cancer cell ablation events followed by treatment‐free intermissions,…”
Get full text

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy by Ebos, John M.L, Lee, Christina R, Christensen, James G, Mutsaers, Anthony J, Kerbel, Robert S

“…Cancer patients treated with antiangiogenic multitargeted receptor tyrosine kinase (RTK) inhibitors show increased levels of plasma VEGF and placental growth…”
Get full text